OncoMatch/Clinical Trials/NCT06663059
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Is NCT06663059 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle and Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle for esophageal cancer.
Treatment: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle · Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle — Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1B-4AN+M0, T2-4N0M0 (AJCC 8th edition)
Locally advanced thoracic esophageal cancer assessed by CT/MRI/EUS, with clinical staging T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk factors such as lymphovascular invasion [LVI], tumor size ≥3 cm, or poor differentiation) (according to AJCC 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: chemotherapy
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Cannot have received: surgery
No prior treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery
Lab requirements
Blood counts
Neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min
Liver function
Total bilirubin ≤1.5 × ULN; ALT ≤2.5 × ULN, AST ≤2.5 × ULN
Normal major organ functions, including: Hematology (no use of blood components, growth factors, white blood cell stimulants, platelet stimulants, or anemia-correcting drugs within 14 days before the first use of the study drug): Neutrophil count ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L; Hemoglobin ≥90 g/L; Biochemistry: Total bilirubin ≤1.5 × ULN; ALT ≤2.5 × ULN, AST ≤2.5 × ULN; Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min; Coagulation: INR ≤1.5 × ULN; APTT ≤1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06663059 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1B-4AN+M0 or T2-4N0M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages